PRLD Prelude Therapeutics Inc

USD 4.77 0.16 3.470716
Icon

Prelude Therapeutics Inc (PRLD) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 4.77

+0.16 (+3.47)%

USD 0.26B

0.03M

USD 6.00(+25.79%)

USD 0.00 (-100.00%)

Icon

PRLD

Prelude Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 4.77
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.26B

USD 0.00 (-100.00%)

USD 4.77

Prelude Therapeutics Inc (PRLD) Stock Forecast

Show ratings and price targets of :
USD 6.00
(+25.79%)

Based on the Prelude Therapeutics Inc stock forecast from 2 analysts, the average analyst target price for Prelude Therapeutics Inc is USD 6.00 over the next 12 months. Prelude Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Prelude Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Prelude Therapeutics Inc’s stock price was USD 4.77. Prelude Therapeutics Inc’s stock price has changed by -1.45% over the past week, +13.84% over the past month and -23.92% over the last year.

No recent analyst target price found for Prelude Therapeutics Inc
No recent average analyst rating found for Prelude Therapeutics Inc

Company Overview Prelude Therapeutics Inc

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial f...Read More

https://preludetx.com

175 Innovation Boulevard, Wilmington, DE, United States, 19805

128

December

USD

USA

Adjusted Closing Price for Prelude Therapeutics Inc (PRLD)

Loading...

Unadjusted Closing Price for Prelude Therapeutics Inc (PRLD)

Loading...

Share Trading Volume for Prelude Therapeutics Inc Shares

Loading...

Compare Performance of Prelude Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for PRLD

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Prelude Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S -1.36 (-1.05%) USD554.45B 46.01 4.80

ETFs Containing PRLD

Symbol Name PRLD's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Prelude Therapeutics Inc (PRLD) Stock

Based on ratings from 2 analysts Prelude Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 3 buy, sell and hold ratings.

Unfortunately we do not have enough data on PRLD's stock to indicate if its a good dividend stock.

Based on targets from 2 analysts, the average taret price for PRLD is USD 6.00 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 5.

Unfortunately we do not have enough data on PRLD's stock to indicate if its overvalued.

The last closing price of PRLD's stock was USD 4.77.

The most recent market capitalization for PRLD is USD 0.26B.

Based on targets from 2 analysts, the average taret price for PRLD is projected at USD 6.00 over the next 12 months. This means that PRLD's stock price may go up by +25.79% over the next 12 months.

We can't find any ETFs which contains Prelude Therapeutics Inc's stock.

As per our most recent records Prelude Therapeutics Inc has 128 Employees.

Prelude Therapeutics Inc's registered address is 175 Innovation Boulevard, Wilmington, DE, United States, 19805. You can get more information about it from Prelude Therapeutics Inc's website at https://preludetx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...